跳至主要内容
临床试验/NCT03924271
NCT03924271Unknown不适用

Prevalence Study of Iron Deficiency in Patients With Cancer

VIFORFRANCE0 个研究点目标入组 1,200 人开始时间: 2019年5月15日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
1,200
主要终点
Blood iron status

研究概览

简要总结

Despite its high prevalence, a recent study conducted by Prof. Cacoub (unpublished) on the french national health insurance database showed that iron deficiency was an underdiagnosed and under-treated co-morbidity. In inflammatory situations, especially during cancer, the measurement of the transferrin saturation factor is only performed in about 10% of cases whereas this measure is recommended in inflammatory situations including cancer (French Health High Authority 2011)

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient, male or female, over the age of 18
  • Patient in an oncology department (any type of tumor, any type of treatment, initiated or not)
  • Patient affiliated or beneficiary of a social security system
  • Patient with written consent

排除标准

  • Protected patient: major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
  • Patient hospitalized without consent

结局指标

主要结局

Blood iron status

时间窗: One day

ferritin, haemoglobin, transferrin saturation factor

次要结局

未报告次要终点

研究者

发起方
VIFORFRANCE
申办方类型
Industry
责任方
Sponsor

相似试验

Prevalence Study of Iron Deficiency in Patients With... | 临床试验